21-12-2017
Hailshadow / iStockphoto.com
Médecins Sans Frontières (MSF) has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Médecins Sans Frontières, MSF, Gilead, hepatitis C, I-MAK, Sovaldi, sofosbuvir, SIPO, State Intellectual Property Office
MSF urges EU to rid market of ‘avoidable suffering’ from SPCs
30-11-2020
MSF critical of EPO decision to uphold Gilead’s hepatitis C patent
17-09-2018
MSF challenges Gilead patent in China
20-06-2018
Non-profit asks US government to take Gilead hepatitis C patent
20-03-2018
Gilead gets Sovaldi patent approval in India despite opposition
10-05-2016
MSF urges Indian Patent Office to reject Gilead Sovaldi patent
02-03-2016
